ArticleInfection2019
Increasing incidence of candidaemia and shifting epidemiology in favor of Candida non-albicans in a 9-year period (2009-2017) in a university Greek hospital.
Article in Infection, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Virulence and resistance factors of Nakaseomyces glabratus (formerly known as Candida glabrata) in Europe: A systematic review.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025Pooled it
- Challenging the Concept of Uncomplicated Candidemia for Shorter Courses of Antifungal Therapy.Open forum infectious diseases · 2026Article
- Observational
- Epidemiology, Risk Factors and Clinical Outcome of Candidaemia:Sultan Qaboos University medical journal · 2025Observational
- Prevalence and Species Distribution ofJournal of fungi (Basel, Switzerland) · 2024Article
- Health of Saudi Women in the Post-Pandemic Era:International journal of women's health · 2024Article
- Article
- Increasing Incidence and Shifting Epidemiology of Candidemia in Greece: Results from the First Nationwide 10-Year Survey.Journal of fungi (Basel, Switzerland) · 2022Article
- Deciphering the epidemiology of invasive candidiasis in the intensive care unit: is it possible?Infection · 2021Review
- Factors associated with the development of ocular candidiasis and ocular prognosis with echinocandin therapy for candidemia.Journal of ophthalmic inflammation and infection · 2021Article
- Antifungal activity of MAF-1A peptide against Candida albicans.International microbiology : the official journal of the Spanish Society for Microbiology · 2021Article
- Efficacy of LAMB against Emerging Azole- and Multidrug-ResistantJournal of fungi (Basel, Switzerland) · 2020Article
- Drug-Resistant Fungi: An Emerging Challenge Threatening Our Limited Antifungal Armamentarium.Antibiotics (Basel, Switzerland) · 2020Review
- The Quiet and Underappreciated Rise of Drug-Resistant Invasive Fungal Pathogens.Journal of fungi (Basel, Switzerland) · 2020Review
- A seven-year surveillance study of the epidemiology, antifungal susceptibility, risk factors and mortality of candidaemia among paediatric and adult inpatients in a tertiary teaching hospital in China.Antimicrobial resistance and infection control · 2020Observational
- Epidemiological Trends of Fungemia in Greece with a Focus on Candidemia during the Recent Financial Crisis: a 10-Year Survey in a Tertiary Care Academic Hospital and Review of Literature.Antimicrobial agents and chemotherapy · 2020Review
- Current Aspects in the Biology, Pathogeny, and Treatment ofInfection and drug resistance · 2020Review
- Species distribution and antifungal drug susceptibilities of yeasts isolated from the blood samples of patients with candidemia.Scientific reports · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe aim of the present study was to analyze candidaemia's epidemiology (incidence, species distribution, and susceptibility rates) and antifungal consumption during a 9-year period.
methodsAll candidaemias recorded at The University General Hospital of Patras, Greece, between 2009 and 2017 were included. Candida isolates were identified using the germ tube test, API 20C AUX System, and/or Vitek-2 YST card. Antifungal susceptibility was determined by the gradient method according to CLSI.
resultsDuring the study period, 505 episodes of candidaemia were observed with an overall incidence of 1.5 episodes per 1000 hospital admissions (1.1 episodes in 2009 to 1.9 in 2017: P 0.038, r 0.694). C. albicans was the leading cause (200 cases; 39.6%), followed by C. parapsilosis (185; 36.6%), C. glabrata (56; 11.1%), C. tropicalis (50; 9.9%), C. krusei (8; 0.2%), C. lusitaniae (5; < 0.1%), and C. guilliermondii (1; < 0.1%). Overall resistance to fluconazole, voriconazole, anidulafungin, caspofungin, and micafungin (according to CLSI) were 11.6%, 4.1%, 2.0%, 6.0%, and 0.8%, respectively. The overall consumption of antifungal drugs was stable, with a significant reduction of fluconazole's use in favor of echinocandins.
conclusionsAn increase in the incidence of candidaemia and a predominance of Candida non-albicans due to decreasing use of fluconazole in favor of more potent antifungals, such as echinocandins, are reported in this study.
Indexed as
Identifiers
30196355What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.